Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term Survival

Clicks: 19
ID: 330738
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #228 of 409 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 409 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Pediatric advanced-stage Hodgkin lymphoma (HL) is highly curable, yet survivors treated with historical regimens face substantial late morbidity and excess mortality. Immunotherapy-based frontline therapies improve disease control, but late toxicities remain unknown. We developed a simulation model to project lifetime outcomes after contemporary brentuximab vedotin- or nivolumab-containing regimens using trial data (COG AHOD1331 and SWOG S1826), Childhood Cancer Survivor Study data, and national databases. We assessed how frontline and relapse therapy changes could influence long-term survival and late-effect outcomes, with sensitivity analyses to evaluate potential immunotherapy-related late mortality. Compared with expected survival at age 50 in the general population, HL survival was 86% at age 50 after historical regimens and 92-93% after contemporary immunotherapy-based therapies. Survival gains persisted unless immunotherapy-related late mortality exceeded approximately 8%. These projections suggest contemporary regimens may narrow the long-term survival gap while reducing late-effect burden.
Reference Key
openalex_W7215071976 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jenna R. Rogers, Zachary J. Ward, Angela Marie Feraco, Sharon M. Castellino, Kayla L. Stratton, Wendy M. Leisenring, Gregory T. Armstrong, Eric Jessen Chow, Rebecca M. Howell, Melissa M. Hudson, Kara M. Kelly, Lindsay McOmber Morton, Kevin Charles Oeffinger, Susan A. Smith, Lisa Diller, Jennifer M. Yeh
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag353
URL
https://doi.org/10.1093/jnci/djag353
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.